News related to Aranesp (Erythropoiesis Stimulating Protein) and/or conditions it is approved for
FDA approves extended dosing of Aranesp
Source: The Doctors Lounge - Hematology
FDA has approved every-3-week dosing of Aranesp (darbepoetin alfa) for treatment of chemotherapy - induced anemia.
AHA: Stroke, VTE More Common with Darbepoetin (CME/CE)
Source: MedPage Today Endocrinology [2009.11.17]
ORLANDO (MedPage Today) -- Treating patients with diabetes, kidney disease, and anemia with the colony stimulating factor darbepoetin (Aranesp) to improve their hemoglobin levels appears to cause more problems than it solves, researchers reported here.
Anemia Drugs May Cause Deadly Blood Clots (HealthDay)
Source: Y! Health News Search RSS Feed [2009.11.10]
HealthDay - TUESDAY, Nov. 10 (HealthDay News) -- New research on cancer
patients adds to the controversy surrounding anemia drugs such as Procrit
and Aranesp, concluding that they increase the risk of venous
thromboembolism, potentially fatal blood clots.
ASN: No Clinical Benefit for ESA in Anemic Patients with Diabetes, CKD (CME/CE)
Source: MedPage Today Endocrinology [2009.10.30]
SAN DIEGO (MedPage Today) -- For patients with type 2 diabetes, chronic kidney disease, and anemia, darbepoetin alfa (Aranesp) failed to improve most clinical outcomes compared with placebo and nearly doubled the risk of stroke, a large, multicenter trial showed.
|
